Key combination for the treatment of first-line AML Recent data from an ongoing study in first-line AML showed a 100% overall response rate (ORR) ...
Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today ...
Oncology leaders appearing in Atlanta, Georgia, including several from Winship Cancer Institute from Emory University School of Medicine, show how NGS biomarkers and MRD reshape NSCLC and hematology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results